6
Diagnosis
4.1. Secondary ASCVD Prevention
COR LOE
Recommendations
IIb B-R 9. In patients with clinical ASCVD who are receiving
maximally tolerated statin therapy and whose LDL-C level
remains 70 mg/dL (≥1.8 mmol/L) or higher, it may be
reasonable to add ezetimibe.
IIb B-R 10. In patients with heart failure (HF) with reduced ejection
fraction attributable to ischemic heart disease who have a
reasonable life expectancy (3 to 5 years) and are not already
on a statin because of ASCVD, clinicians may consider
initiation of moderate-intensity statin therapy to reduce the
occurrence of ASCVD events.
* Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome
(ACS), those with history of myocardial infarction (MI), stable or unstable angina or
coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or
peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin.